Yandex injects 600G wavelengths into DCI network with ADVA TeraFlex™
5.11.2020 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Yandex has transformed its data center interconnect (DCI) infrastructure into a 600Gbit/s transport network using the ADVA FSP 3000 TeraFlex™. The solution massively increases the capacity of Yandex’s infrastructure throughout Moscow, enabling Russia’s largest search engine provider to meet rapidly rising data demands and expand its cloud services. Delivering high levels of throughput, density and scale, the technology easily plugged into Yandex’s existing line system. ADVA’s open TeraFlex™ terminal supports 600Gbit/s over a single wavelength and delivers a total duplex capacity of 3.6Tbit/s in one rack unit. With its low power consumption and ultra-flexible modulation capabilities, TeraFlex™ ensures maximum spectral efficiency, making Yandex’s DCI network future-proof and highly efficient.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005031/en/
ADVA's TeraFlex™ technology is helping Yandex to easily scale its DCI network (Photo: Business Wire)
“We’re proud of what our FSP 3000 TeraFlex™ technology is helping Yandex achieve. Without the effort or expense of a complete system upgrade, it’s enabled one of Russia’s biggest technology companies to transform its infrastructure. By unlocking the full value of its fiber assets, Yandex is opening the door to further growth and innovation,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our TeraFlex™ has a large degree of configuration flexibility, using different modulation formats and software-defined fractional QAM to optimize data rate transmission performance. Together with its plug-and-play simplicity, TeraFlex™ made it easy for Yandex to transform its existing DCI infrastructure.”
Yandex’s Moscow data centers are now connected in a point-to-point network with ADVA’s high-density TeraFlex™ terminal. Serving 36 bidirectional 100GbE client ports, the 1RU solution injects new levels of channel capacity and spectral efficiency into Yandex’s network. Built specifically to maximize fiber utilization, TeraFlex™ features software-defined fractional QAM modulation capabilities. This enables it to leverage different modulation formats and optimize all optical paths over any distance.
“We’re helping Yandex to massively expand the capacity of its network and accommodate ever-increasing traffic demands. Our TeraFlex™ terminal is ensuring that one of Russia’s leading technology companies can meet its customers’ expectations and continue growing its business well into the future,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Tens of millions of people rely on Yandex’s products and services on a daily basis. That’s why it’s a company keen to deliver even more by leveraging the most advanced technology on the market. Our solution enables it to continue innovating and improving quality. And, with the space- and power-efficiency of TeraFlex™, Yandex’s new network also ensures that future growth is fully sustainable.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005031/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom